Amicus Therapeutics, Inc.

FOLD

US03152W1099

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:58:15 23/05/2024 BST			5-day change	1st Jan Change
9.415 ^USD	-3.14%		-0.63%	-33.47%

05-15	Transcript : Amicus Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM
05-14	Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target	MT

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

May 09, 2024 at 12:00 pm

Amicus Therapeutics, Inc. provides earnings guidance for the year 2024. For the period, the company expects Total Revenue Growth 25% to 30%.

Latest news about Amicus Therapeutics, Inc.

Transcript : Amicus Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM	05-15
Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target	05-14	MT
UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating	05-10	MT
Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise	05-09	MT
Transcript : Amicus Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Amicus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	05-09	CI
JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	03-18	MT
Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	03-05	MT
Transcript : Amicus Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises	02-28	MT
Earnings Flash (FOLD) AMICUS THERAPEUTICS Posts Q4 EPS $0.01, vs. Street Est of $-0.04	02-28	MT
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	02-28	CI
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Amicus Therapeutics Insider Sold Shares Worth $390,018, According to a Recent SEC Filing	02-08	MT
Amicus Therapeutics Insider Sold Shares Worth $683,958, According to a Recent SEC Filing	01-24	MT
Amicus Therapeutics Insider Sold Shares Worth $404,106, According to a Recent SEC Filing	01-18	MT
Amicus Therapeutics Insider Sold Shares Worth $934,659, According to a Recent SEC Filing	01-12	MT
Amicus Therapeutics Insider Sold Shares Worth $449,545, According to a Recent SEC Filing	01-10	MT
Transcript : Amicus Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 02:15 PM	01-08
Amicus Therapeutics Sees Revenue Growth of 21% in 2023	01-08	MT
Amicus Therapeutics, Inc. Announces Unaudited Preliminary Revenue Results for the Fourth Quarter and Full Year of 2023	01-07	CI
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	01-07	CI
Amicus Therapeutics Insider Sold Shares Worth $734,007, According to a Recent SEC Filing	01-05	MT
Amicus Therapeutics Insider Sold Shares Worth $490,411, According to a Recent SEC Filing	12-29	MT

Chart Amicus Therapeutics, Inc.

Duration

Period

More charts

Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Amicus Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.72 USD

Average target price

17.3 USD

Spread / Average Target

+77.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AMICUS THERAPEUTICS, INC.	-33.47%	2.88B
MODERNA, INC.	+63.99%	62.59B
IQVIA HOLDINGS INC.	-1.92%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+12.50%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.93%	19.09B
BIO-TECHNE CORPORATION	+3.89%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.37%	12.26B
MEDPACE HOLDINGS, INC.	+27.38%	12.05B

Other Biotechnology & Medical Research